Inhibrx Biosciences, Inc. (INBX)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS45720N1037
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Inhibrx Biosciences, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:06. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 13 Nov 2026 16:00 | -2.35 | — | — | Upcoming |
| 13 Aug 2026 16:00 | -2.28 | — | — | — |
| 14 May 2026 16:00 | -1.20 | -2.15 | -79.2% | Miss |
| 19 Mar 2026 16:00 | -2.08 | -2.11 | -1.4% | Miss |
| 14 Nov 2025 06:00 | -1.72 | -2.28 | -32.6% | Miss |
| 13 Aug 2025 16:00 | -2.60 | -1.85 | +28.9% | Beat |
| 14 May 2025 16:00 | -3.12 | -2.80 | +10.3% | Beat |
| 17 Mar 2025 16:00 | -2.88 | -4.47 | -54.9% | Miss |
| 14 Nov 2024 16:00 | -3.70 | -2.84 | +23.2% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 1.3M | +550.0% | -140.1M | -10,773.5% | -9.04 | -108.0% | -129.8M |
| 2024 | 200K | -88.9% | 1.7B | 843,786.0% | 112.62 | +764.5% | -197M |
| 2023 | 1.8M | +38.4% | -241.4M | -13,408.9% | -16.95 | -109.3% | -197.9M |
| 2022 | 1.3M | — | -115.3M | -8,864.3% | -8.10 | — | -91.5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 86.39 | 93.48 | 84.00 | 84.00 | -0.62% | 729,512 | |
| 02 Nov 2026 – 06 Nov 2026 | 72.45 | 87.13 | 70.87 | 84.52 | +17.75% | 1,487,000 | |
| 26 Oct 2026 – 30 Oct 2026 | 93.80 | 99.88 | 66.80 | 71.78 | -23.13% | 2,611,200 | |
| 19 Oct 2026 – 23 Oct 2026 | 90.43 | 100.20 | 88.21 | 93.38 | +3.95% | 1,042,500 | |
| 12 Oct 2026 – 16 Oct 2026 | 94.03 | 96.10 | 83.61 | 89.83 | -5.45% | 1,106,300 | |
| 05 Oct 2026 – 09 Oct 2026 | 97.56 | 98.50 | 90.15 | 95.01 | -2.04% | 894,900 | |
| 28 Sep 2026 – 02 Oct 2026 | 98.69 | 107.90 | 96.07 | 96.99 | -2.63% | 1,236,500 | |
| 21 Sep 2026 – 25 Sep 2026 | 112.69 | 117.14 | 98.09 | 99.61 | -8.91% | 1,360,900 | |
| 14 Sep 2026 – 18 Sep 2026 | 109.10 | 111.44 | 99.06 | 109.35 | +0.07% | 1,555,100 | |
| 08 Sep 2026 – 11 Sep 2026 | 117.22 | 128.54 | 94.00 | 109.27 | -9.82% | 2,874,900 | |
| 119 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price (opens in a new tab) Simply Wall St. · 23 Oct 2026 11:16
- Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility? (opens in a new tab) Simply Wall St. · 14 Oct 2026 15:14
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup (opens in a new tab) MarketBeat · 02 Oct 2026 13:00
- Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating (opens in a new tab) Simply Wall St. · 29 Sep 2026 12:08
- Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? (opens in a new tab) Insider Monkey · 24 Sep 2026 18:07
- Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? (opens in a new tab) Motley Fool · 16 Sep 2026 01:29
- Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data (opens in a new tab) InvestorsHub · 08 Sep 2026 13:51
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 87.75 USD
- Market cap
- 1.3B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow INBX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.